A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYC

Phase 1

• Conditions: Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis

• Registration Number: EUCTR2006-001663-33-GB
• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-31
• Study Completion: 2013-02-14
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 140

Inclusion Criteria

Inclusion (requires all)
i)New diagnosis of AASV (WG or MPA) (within the previous six months)
ii)Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1)
iii)ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix )
iv)Written informed consent

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion
i)Previous treatment with:
(1)MMF: more than two weeks ever.
(2)Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg)
(3)Rituximab or high dose intravenous immunoglobulin within the last twelve months
ii)Active infection (including hepatitis B, C, HIV and tuberculosis).
iii)Known hypersensitivity to MMF, AZA or CYC.
iv)Cancer or an individual history of cancer (other than resected basal cell skin carcinoma).
v)Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.
vi)Any condition judged by the investigator that would cause the study to be detrimental to the patient.
vii)Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.
viii) Active serious digestive system disease (e.g. inflammatory bowel disease)
ix) Patients with imminently life threatening vasculitis (diffuse aleolar haemorrhage, intestinal perforation or major haemorrhage, cerebral vasculitis and cardiac vasculitis).
x) Patients with rapidly progressive glomerulonephritis and declining renal function. Defined as estimated GFR fall >20% in previous two weeks.
xi) GFR <15mls/min at entry or on dialysis.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified